Skyhawk Therapeutics Says to Work With Merck to Develop Drug Candidates
July 08 2019 - 8:29AM
Dow Jones News
By Michael Dabaie
Skyhawk Therapeutics Inc. said it is in a strategic
collaboration with Merck & Co. (MRK).
The company said it is collaborating with Merck, which is known
as MSD outside the U.S. and Canada, on small molecules that
modulate RNA splicing for the potential treatment of certain
neurological diseases and cancer.
Skyhawk said it is eligible to receive about $600 million per
program target consisting of an upfront cash payment and, if Merck
exercises its option, potential opt-in fees, milestone payments, as
well as royalties on sales of commercialized products.
Skyhawk will grant Merck the option to exclusively license
worldwide intellectual property rights to candidates discovered and
developed under the collaboration that are directed to program
targets.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 08, 2019 08:14 ET (12:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024